Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

In the Interim...

In the Interim... artwork

Digital Googols

Oct 27, 202538 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of "In the Interim…", Dr. Scott Berry examines the concept of “digital twins” in clinical trials. He details how simulation of clinical trials is a direct analog of digital twin methodology, allowing for the in-silico modeling of the physical trial conduct, enrollment, dropouts, and patient outcomes under varied assumptions. Scott discusses model-based patient prediction and highlights scenarios where prediction of counterfactual outcomes can increase efficiency, particularly in rare disease or limited-data settings. He provides a systematic comparison of Unlearn’s PROCOVA neural network approach with traditional covariate adjustment, noting that proprietary models must demonstrate clear improvement over standard methods, which is unlikely. There is great potential in the simulation of many digital twins for a patient as a potential augmentation or substitute for controls. Key Highlights Defines digital twins using NASA history and Wikipedia. Describes clinical trial simulation as a digital twin methodology. Examines patient-level model-based prediction and covariate adjustment. Compares Unlearn’s PROCOVA with traditional approaches. Highlights transparency and reproducibility concerns with proprietary algorithms. Asserts that future trial efficiency demands integration of predictive modeling with randomization and large external datasets. For more, visit: https://www.berryconsultants.com/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Judith: Welcome to Berry's In the Interim podcast, where we explore the cutting edge of innovative clinical trial design for the pharmaceutical and medical industries, and so much more. Let's dive in. Scott Berry: Welcome everybody. Back to, in the interim, I'm Scott Berry, your host. So I, for those of you who join us in the interim frequently, you may notice, uh, my background is different than our usual studio. Uh, it's, uh, stunningly beautiful place and I will, I will lift the

camera up a little bit and show that I'm actually in Southern California. Uh, taping here next to the grand old Pacific Ocean. And it's beautiful. Um, or am I, and, and many of you who join, uh, uh, webinars, uh, zoom meetings, lots of people have virtual backgrounds and a lot of people have the same virtual background. Makes 'em look like they're in the same office.

Uh, so you don't know. If I'm actually on the Pacific Ocean or it's virtual digital and I am stuck in the bowels of my attic in Austin, Texas, or I really am on the coast, so by the way, I am of course, am I? Am I Scott Berry or am I a digital twin of Scott Berry? So that's my topic for today are, are digital twins.

And it, it's been a term used, uh, in clinical trials. It plays a role in clinical trials. It plays a role in ai. What is it besides perhaps. A picture of the, the, the Pacific Ocean, which is not a digital twin. A a picture of something is not a digital twin, but let's talk about what it is, how they're used in trials, the potential of them. And my viewpoint, I've actually asked quite a bit within trials, we do a lot of adaptive trials, hence sitting in the interim of, of a clinical

trial, uh, right now where you are. Or, and we do a lot of Bayesian analyses, which can be separate from using external data. You can do Bayesian analyses without using external data, but when you use external data to a trial, the Bayesian approach is a really powerful thing. So we end up doing quite a bit of trials using external. Yeah, digital twins are external in some sense, to the clinical trial. So I'm asked a lot about digital twins and so I, I, I will give you my viewpoint

today here, uh, uh, in the interim. So the name digital twin. Uh, is, is I, I'll tell you what Wikipedia says. A digital twin is a digital model of an intended or actual real world physical product system or process. A physical twin. That's the physical thing that we're actually interested in. It serves as the effectively indistinguishable digital counterpart

of it for practical purposes, such as simulation, integration, testing, monitoring and maintenance. So a digital twin is a. A creation a, a model-based creation, a simulation of a real physical thing that's of interest. The original term traces back to NASA, where they're creating digital. Simulations digital twins of a physical characteristic.

This could be a rocket ship, this could be a new airplane. This could be many different, uh, interesting physical things that we can't do a ton of testing on. You could imagine the Department of Energy doing this for, uh, uh, tests of nuclear testing where. We can't just be blowing things up. So we're creating digital twins of that physical system. Incredibly powerful, but of course powerful to the extent of its

realism and in in this scenario. So. Let me give you an example of a digital twin that you, we've never called a digital twin before, but it is completely a digital twin, and it's something we do quite a bit of, which is clinical trial simulation. The, the Wikipedia definition of a digital twin talks about simulation. We, in the design of clinical trials, we create an silico digital version.

Of the physical trial. The physical trial is run once. We don't want to go run 10,000 physical trials to figure out the best way to design that trial. What's a good trial that would be, you know, many, many years we can't do it. So we create a clinical trial simulation of that physical trial. We try to create it with an, with all of the needed detail of

the things we're going to vary. So we, we, we do enrollment rates, variability to enrollment rates. Typically a s on process of that, where there, there's ramping up of sites. We incorporate dropouts of patients, the behavior of patients on the controls. Maybe they're seeing regression to the mean within that scenario, then we simulate their outcomes in the trial with variabilities to their outcomes. We even test treatment effects in that.

So we create this digital system that has value to us as a digital twin of that physical system, of that single physical trial that we run once the value of this is now in silico, this, this simulation. We can do things to that. We can add response, adaptive randomization to it. What if we change the design to have that?

Then we run it tens of thousands, millions of times, and we look at how well does it work. Does it get the right answer where we feed in the right answer to it? This might be very similar to what NASA does, where they're simulating different aerodynamics to the systems, different weights to the system. What if we alter the wing shape to it? How is it going to behave? What if we change the material to it? That's what we're doing when we're doing clinical trial simulation.

We vary it. We vary the design. And we look at how well does it fly? Does, is it, is it efficient in its flight? Does it get to the right answer? Where the beauty of it is, we're pumping in the right answer. At the same time, we, we get to play the role of Mother Nature and say, suppose the treatment has a 50% effect. Does the trial, the clinical trial simulation get the right answer? Now, there are critics of this.

Um, and they're, they're critics of clinical trial simulation. And of course the clinical trial simulation is only as valuable as how it reproduces reality of the physical system. Now, usually when we're doing it, we put in the detail needed to test the things we're gonna test. We may not put in there detailed aspects of the biology of a patient, because that's not what we're interested in.

We're not actually PKPD do digital twin simulation of the human body. What happens when we give this drug and it's half life is a certain thing. What happens to the physical system? And how do they forecast outcomes? It's a beautiful thing. That's not my specialty. I I, I don't do that. But we do it in a clinical trial. We do it to the detailed needed. So there are critics of simulation and in some ways, if you could analytically calculate all these things, you don't need simulation when doing a simple

fixed trial of a single endpoint. And you're interested in the power. We, we can go look this up in tables. We, we have simple formulas. We have analytical characterization of that physical system that you don't need simulation. And you can ma, you can imagine an absolute brilliant person that can do analytical work way beyond my capabilities. Say We don't need simulation.

I can do this analytically. Now I think that only works to an extent of the complexity of your design, and it can be limiting in the complexity of your design. If you believe we have to analytically understand the trial, it immediately sets the complexity to, to a level that I, I, I think is limiting. Okay, but we want to understand this, where we understand the role of dropouts add really more complex designs.

10, 15 analyses. We're dropping patient character, patient types. We're changing randomization. We have multiple arms in the trial. To a complexity that you can't do it analytically. And then this is a hugely valuable thing to have this digital twin of the physical system. And then we alter it and we create a better design. So this little rub of analytically and simulation is going to to to, to play a role in multiple ways.

Anytime somebody creates a digital twin, there's going to be this rub now. Digital twins aren't brought up as clinical trial simulation in the world of clinical trials, but it is absolutely a digital twin. Digital twins are a term that a company is using. The company's name is unlearn. I, I, I, I don't have any relationship to any to, to unlearn. I, I, I've talked to them.

I think they're, they're, they're quite brilliant and they've, they've created something and it, it may be even some level of proprietary where they label things as a digital twin, and that's been making its way. But this whole concept is also really a quite powerful thing within clinical trials. The use of it in clinical trials has usually been about a patient. Can we create a digital twin of a patient, not to a biologic level of

what are the level of cholesterol, and then giving them a statin? What happens biologically, but one where we create a digital twin of what their endpoint would be in a trial or endpoints of interest. If they were on a control, if they behave in a way that we have previous data, that we can create a potential digital twin of that patient. So, uh, we'll use as an example, a couple examples, and I think unlearn

talks about Alzheimer's and a LS. And so we have a patient that comes in in a clinical trial. They have a baseline CDR sum of boxes. They have a baseline amyloid level, they have baseline MMSE level, and we're gonna run a trial where we're going to look at 18 month outcomes of that patient. And we're interested in what is that patient's CDR sum of boxes. This is a clinical dimensional.

Clinical dementia rating scale endpoint commonly used in Alzheimer's trials. And we would like to understand what is going to happen to that patient if they were given a placebo 18 months from now. What is their CDR sum of boxes going to be. Incredibly powerful thing. Uh, if, if we can do this now. Think about why we run a clinical trial.

We run clinical trials where we give a treatment to a patient, and what we really want to know is the counterfactual of what would've happened to that patient Jane Doe if we didn't give them the treatment in a, in an Alzheimer's trial. Their CDR sum of boxes goes from one to four in the trial. What would've happened if we didn't give them the treatment? Would it have gone one to seven, higher values are worse on that input?

Would they have been worse? Would they have been better? Would they have been exactly the same? That's why we run a trial. It's why we randomized patients in a trial to no treatment. So that we see some patients under the counterfactual, uh, they're, they're not actually the counterfactual, they're the factual of giving them a placebo. We, we observe what happens under placebo and what happens under treatment. Imagine the power that we could give 500 patients a treatment.

And we could just say, what is the digital twin of that patient from 18 months? And we analyzed the trial. I'll talk a little bit more about how, how, how would you do that? But we analyzed the trial. So comparing to that, our trials can be less than half the size actually, because there's no, there's no variability to that. Maybe we need to characterize that. But imagine if you could say, Hey Alexa, what would've happened to Jane Doe? Without this experimental treatment, incredibly powerful.

It's why we randomize, and it's why we do clinical trials. It's why we do blinding. It's why we do all of the scientific aspects of these trials, and it's why they're quite large, quite expensive, is to get that honest answer to it Now. Let's revisit a little bit of what Unlearned does, because I think it's important because they have come out with an announcement and you can go look at unlearn and you can look at their news where the, the, the title

of their press release is that the European Medicines Agency qualifies unlearned AI powered method for running smaller, faster clinical trials. So the immediate thing is, oh wow. We're doing this, what, what, what Scott said about, uh, uh, creating a digital twin and we're comparing it to the digital twin and EMA has qualified this, so I think you have to take a step back. So what, what, what have they qualified?

Uh, of course there's this comment of AI powered, we'll, we'll come back to that. This AI powered method for running smaller, faster clinical trials. So, and you can go read this on Unlearned, but what Unlearned does is they have data, they have historical data on Alzheimer's or a LS or the disease. You need it where they create in AI based model. And it says on their website that they use deep neural networks.

So this is a little bit about trying to get into the details statistically. We understand a little bit about what this means to predict or model digitally. What would happen to a patient 18 months from now? So they create this neural network model. They call it an AI model, but it's a, it's a neural network, and it's not just a neural network. It's a deep neural network to do this forecast.

Their forecast is not a single patient forecast with variability to it. It's essentially a model mean prediction. It's a model average prediction of a neural network based on their data of what that patient would do with a LS, with Alzheimer's, with cardiovascular disease, with weight loss, whatever it is they're trying to do. That's what it is. It's a single model prediction.

Now, what has EMA qualified, it's not that that. Digital twin is a comparison to a patient on treatment. They use it in what they call pro cova. It's a covariate adjustment. Now, in in modeling, you've probably heard of an ancova where we use a baseline covariate. Baseline CDR sum of boxes to adjust for the 18 month value.

That's an ancova. So this is a pro cova, and this is that you use the predicted value of 18 months for that digital twin. You put that in as a covariate to the model, and all of that is based on baseline things. Very legitimate thing to do. And that's your covariate. So this deep neural network value based on the historical data is your covariate and you put it in for treatment and control.

It's, it's, think of it as a value of p this prediction for every patient, they, they put it in the, the, this AI powered thing. And what comes out of it is an 18 month value of 3.7, and that goes in as a covariate in your model. And this creates smaller, more efficient trials. So what, what are the benefits here? Now what? What's an alternative to this? An alternative to that is that you put in the baseline value, you put in their

amyloid value, you put in their MMSE, you put in characteristics of that patient as covariates in the model and. The, the trial fits those covariates based on the patients in the trial in both arms and, and really that covariate adjustment is providing a prediction of that patient at 18 months. That prediction balances out the two treatment arms in the scenario.

It allows us to reduce the variability of this outcome at 18 months. If we don't do any covariate adjustment, there's more variability, but by Covariate adjustment, we reduce that variability substantially in many circumstances. Baseline CDR, sum of Boxes, amyloid value, MMSE, Addis Cog plugged in is going to reduce the variability of the 18 month outcome. Incredibly important. So now let's compare those two things. One trial uses baseline covariates and does not use unlearned, uh uh, EMA

qualified thing, just baseline covariates. It's doing this adjustment. There's gonna be a certain variability to the 18 month outcome after adjustment. The other trial uses this pro cova digital twin adjustment. Yeah, there's gonna be a certain amount of 18 month variability. The role of both of these are identical. That's all these this is trying to do. So that AI method has to be better than the covariate adjustments in our model,

and I doubt it in most circumstances. I highly doubt in most scenarios that we have that there might be some. And so we'll talk a little bit about when that might be of value. So two things. First of all, if I have the data that this unlearned machine has, I, we, we, we can do just as well. You, you could do, you could do just as well. Now, I'm not saying barrier, you could do just as well to use that as covariate. Figure out the right way to model a covariate.

And, uh, you know, does this deep neural network do adjustments or predictions of that 18 month value better than linear covariates or, or might, might even be quadratic covariates. You could learn based on that data the right way to do this. I, I don't think so. I, I, it's, I think it's a lot of Blu. And I, it, it's, sure. I think it's very reasonable if you do it. I, I, I've got no qualms to it, and I think it's a very reasonable thing to do. I just have my doubts as to whether this is actually better.

I, I, I, I doubt it. What, where's this scenario? It might be better. Let, let's be reasonable and think about where's this scenario where this might be better. Suppose they have a couple hundred patients in a rare disease that you don't have in a scenario. And you are not sure how to do covariate adjustment in it, and they can provide this prediction. I think that could be of value, where you don't have the data, you don't know how to do this covariate adjustment. This could be a very reasonable thing to do, uh, in that scenario.

Now, in a scenario, let's, let's think of A-L-S-A-L-S, by the way, has this incredible resource, the ProAct database. Is this incredible resource in a LS that has natural history of pat of, of a LS patients' behavior, randomized placebos in there. They might even have active treatments in this, this data set. I, I, I'm not sure of that, but it's an incredible resource. I'm sure when Unlearn does their, their, their deep neural

networks, it's using that database. So I, I don't think there's value there. If you have the same data they have in the scenario for a couple reasons, I think you could figure out the right covariate adjustment times in since onset of disease. And a LS is a good predictor. Their their current A-L-S-F-R-S-I, I I think you could do really, really well in there. And you don't need this AI powered thing. I'm not even sure it's better, but they don't tell you what the model is. It's proprietary.

So they give you a value of 3.1, but you don't know what the model is. I, I don't think that's the way forward here, and I think it's a bad way forward with ai, um, in clinical trials. I think we need that model written down. I think we need that model to be verified and, uh, uh, reprogrammed and, and, and, oh yeah, we generate, we get the same value to that. I think if digital twins go this route, that.

It's this super secret deep neural network thing, and it gives you a number that's bad and that's a bad way forward for clinical trials. Now, I, I don't wanna fault unlearn. I, I, I think there's actually, they may be doing things that are hugely valuable and even if that's out there, people are gonna want to see it and use it in scenarios. So what are the benefits of it is a covert adjustment. I think it's a lot of. Not, not much, uh, in there, in, in these scenarios.

Uh, so, but what, let's think about the future. Let's think about where this is going. We are going to get really good at the prediction of an individual patient level. I mentioned this ProAct database, a LS. In a clinical trial, when a patient comes in, we can make really, really good prediction of where that patient would be under natural history. Incredibly good.

We don't actually take advantage of that much in, uh, clinical trials. We're still randomizing. I'm not saying that's the wrong answer, but we're gonna get really, really good. And I made, I, I was playing light of it by saying, Hey Alexa, what would happen to this patient? We're gonna get really, really good at that. And moving forward, we have to utilize that. And we're gonna get really good at that in a lot of different syndromes where

we get a snapshot of a patient at a point in time and we're gonna be able to have a really good prediction of that. But let's think about that a little bit. So, so going forward, I think this whole digital twin technology, and we're gonna start calling it different things because this can be slightly confusing, model based estimate of a patient. Are going to become incredibly powerful things moving forward. It has to, now, we have to come to grips with the causal aspects of this.

We have to come to grips with the, the bias in who enters a clinical trial, is it characterized by baseline? And there's still gonna be huge value in randomization, for example. So imagine a clinical trial where you do this and you randomize three to one. Treatment to control, and you've got the model based predictions that are part of the primary analysis, but you have real placebo patients to identify, are we doing this well?

And they're randomized placebos. That's a patient that you enroll and you say, we have a prediction of that patient if we do nothing to them, and then we get the value of doing nothing to them, which can verify and validate within your experiment. The whole notion of digital twins, this becomes really, really powerful. So this, this combination of treatment controls continually verifying and validating using less patients and, and, and, and allowing a great deal of

more certainty to that, to understand whether a treatment is working. Is the future? If it's not the future, we're not doing this right now. Where are we now? This is actually being done. It's not necessarily called this, and that might be a good thing. So in a number of scenarios, we do this. Actually, propensity modeling is that. Where you have a historical database and you wait certain patients to be

a digital version of this patient, we've just enrolled and then we wait. Their outcomes, it's digital twins. We do quite a bit at Barry, where we model historical databases and we create a model based estimate of a patient. We do this in a LS. Where we create forecasts of a patient enrolled in a trial and what they're going to look like. We do this in FTD, we do this in Alzheimer's.

We do this in a, in many diseases. We've done it 50 times. Now what's what's interesting here is what do you do with this? I want you to think about a scenario where what we get in a trial is a distribution. O and now I, I'm, I'm sure unlearn has some level of prediction, variability and all of that. I don't think it's part of the pro cova stuff. Uh, they, they have to do this to some level, but it's not going to be

that we simulate a single patient. As a payer, it's wholly inadequate. We need to simulate a million. And that's actually a distribution that, that's what we know analytically as a distribution. So coming back to this issue of clinical trial simulation where we do a lot of clinical trial simulation and we have critics, I think Steven Sen has been a critic publicly on Twitter of simulation, um, uh, within that.

And he fits into this category of this brilliant person that can do analytical things, uh, in that. We might be critics of, uh, a single simulation of a single patient of, I want a million, I want a Google number of them, which is actually just an analytical distribution for every patient that walks in the door, Jane Doe comes into a clinical trial. We want a distribution of that patient.

And the title of this, this, uh, in the interim is digital Googols um, which is 10 to the hundred, uh, twins digital Googols of this is just a distribution. It's an analytical characterization of that patient. Now how do we, how do we do this in a trial? How do we do P values? How do we do Bayesian posterior probabilities? Now, in many of our trials, that model that we've created has a mechanistic

effect, like a rate of decline. Or as a mechanistic behavior that going into the trial, we can actually include that as what is the rate of decline for patients on a treatment relative to control? And we're estimating a theta in a, in an oncology trial. Imagine if we have the, the behavior, uh, and, and the overall survival. Distribution of a patient that comes in the door that has a certain

characteristic with a certain, uh, uh, uh, cancer, we could then create this, this, this characterization, this, this model-based estimate of their time of overall survival. And we can fit a hazard ratio based on the individual patients that come into that. So that's a little bit of one step forward. Of using the model based digital virtualization of that patient to characterize treatment effect, which can be incredibly powerful,

especially under neurological diseases, progressive diseases. This can be incredibly powerful. I'll throw out one where this, this has to be the future is Duchenne muscular dystrophy. We've had a number of successful, a number of controversial things. We have great data sources. They're actually not as accessible as ProAct. It's actually one of the issues, but it's going to become accessible. We're going to have these phenomenal data sources.

We've just gotta get rid of the roadblocks to that, and we're going to use these, and we're gonna have this incredible virtual characterization of a patient we know. What's gonna happen to a 4-year-old boy with Duchenne muscular dystrophy that walks 240 meters? We can, we can show virtually what's gonna happen. Can we characterize that and put that in there? So it's a little bit of a different trial. The way forward of this is not, yeah. So think about what we do now in trials.

We have a, a treatment and a placebo, and we run things like T tests. We run MMRM models. We're not gonna do that. With a single paired observation of that, it it in a, in a trial. Imagine you run a, a randomized trial where we have a Google number of patients on placebo. That's what we have, and we're gonna have to figure out the statistical way to do that. And we've done that. You can do non-parametric tests where the, the, the, the model

simulates a million observations. Of that single patient under control. And then you get the one observation only in the physical system of that patient on treatment. But we've got no uncertainty in this, this, this, uh, distribution. So these, these are gonna be really cool. And really cool trials going forward. I think that model has to be written down, verifiable. Uh, people can go back and make it better as we go forward.

As you get more and more data, it has to be included into this. Imagine this system what it is. It really is a disease. Alexa. What is going to happen under this patient? And the characterization is unbelievably promising within that. And I, I think that's the way forward. So in a way, I don't want you to think, oh, Scott's, Scott's critical of digital twins. I, I might be the most excited person out there for, for this virtualization

of a patient in ways that I think models can do this really, really well. And what it prevents is. Putting a lot of patients on a control, think about how many patients we put on a control, and first of all, randomized trials are so incredibly valuable. We're seeing the reason for it within current healthcare policy and all of this. A complete lack of understanding of the role of this, the need of it, the conclusions that come out of it compared to.

Misbehaving uses of, uh, uh, other use of data. So randomized trials are, are absolutely unbelievable and they won't go away. I think we'll continually randomize, but this idea that five trials out there all randomized, 50% of their patients and we're enrolling patients under a something and we know what's gonna happen to them, we have an incredibly good idea. It's bad. It's incredibly inefficient as a system, so we have to get there. We have to move there faster.

Now it's only as good as the data and. 20 years ago, it just didn't exist. We didn't really didn't have these data sources. It exists. Some data sources existed within pharma, some existed within the NIH, some existed at other places. You couldn't get your hands on it. We still have this issue. We still don't have great access to data, but it's getting better. Uh, medical systems, data sources out there.

I, I think there's gonna be an explosion of data, and it's going to be to the point that we don't know what to do with it. Let me give you another circumstances of it. So, I, I wear a whoop band. It's like a, it's like a, a, a, a watch, uh, a wearable that tracks all kinds of things about. Um, in, in terms of my heart rate, my blood pressure, uh, my strain on the day, how much I sleep, it's gonna characterize things about my behavior,

how fast I walk, how big my gait is, how much I type, all kinds of things that are gonna characterize people in ways that what are we gonna do with this data? It's phenomenally powerful. So we're gonna need really good models to do this. It might be neural networks that do this. Now they need to be accessible, uh, within that. And if this goes, you know, they need to be open source to some extent if we're gonna use them in these incredible, powerful ways.

So, oh, virtualization. Whether behind me is the Pacific Ocean, you may not know. Um, uh, in these trials, but this whole idea of virtualization as, as counterfactual in trials is incredibly powerful. Uh, I, I think that this is the future. We're not, we are there and this is being used. External data's being used in trials in really, really powerful ways. It's, by the way, it's always been used. We, we've, we've approved drugs based on single arm trials.

And it's been compared to what we think historically, what would've happened to those patients? An ORR rate that just seems that it could never have happened based on historical ways to treat patients. We're getting better and better and better at it's coming into rare diseases, it's gonna be coming into common diseases. It, and this notion as a system of enrolling all these patients on a control just seems, wow. Uh, incredibly inefficient. So thank you for joining me here in the interim.

Until next time, I am Scott Berry, your host, or at least you think I am.

Open the transcript file

Hosts and Guests

Hosts

  • Scott Berry Host Feed-stated

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Can Borrowing Ever Increase Power?

    Nov 16, 202625 minAudio

    In this episode of "In the Interim…", Dr. Kert Viele, Director of Research at Berry Consultants, takes up a requested topic: published results showing that Bayesian borrowing of historical control data cannot increase...

    Credit the people on this episode

  2. Mailbag: Learning Healthcare, Multiplicities, and the Pace of Innovation

    Nov 9, 202647 minAudio

    In this mailbag episode of "In the Interim…", Dr. Scott Berry answers two listener questions and weighs in on the pace of innovation in clinical trial science. Asked what infrastructure a learning healthcare system...

    Credit the people on this episode

  3. Reflecting on EMA Reflections on Platform Trials

    Nov 2, 202644 minAudio

    In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele, Director of Research at Berry Consultants, review the European Medicines Agency's draft reflection paper on methodological aspects in...

    Credit the people on this episode

  4. Statistical Methodology Groups in the Pharmaceutical Industry

    Oct 19, 202656 minAudio

    In this episode of "In the Interim…", Scott Berry is joined by Jenny Devenport and Kaspar Rufibach of Merck Group, co-authors of the EFSPI Statistical Methodology Leaders paper "Statistical Methodology Groups in the...

    Credit the people on this episode

  5. A Discussion on Virtual Controls

    Oct 12, 202647 minAudio

    In this episode of "In the Interim…", Dr. Scott Berry shares the framework he presented at a CSRC regulatory science hackathon on digital twins and synthetic controls in cardiovascular clinical trials. He separates...

    Credit the people on this episode